Newormics launches new vivoChips for early stage worms

Early larval stages of C. elegans (L1 to L3) have always been among the hardest to immobilize and image successfully, due to their tiny size and difficulties with using conventional anesthetics and mounting methods. To help researchers solve these problems, Newormics is launching two new devices in our vivoChip™-2x range: vivoChip™-2x L1-L2, for immobilizing L1 Read more about Newormics launches new <em>vivo</em>Chips for early stage worms[…]

Newormics at the 2019 UK C. elegans meeting

Newormics is exhibiting at the 2019 UK C. elegans meeting at Imperial College London on September 16th. Come meet us and view our latest imaging solutions there. We will also have a special laboratory demo day, kindly hosted by Dr. Michalis Barkoulas at Imperial College London on September 17th. The demo will allow attendees to Read more about Newormics at the 2019 UK <em>C. elegans</em> meeting[…]

Newormics awarded an SBIR Phase I grant from the NIEHS

Newormics was awarded an SBIR Phase I grant from the National Institute of Environmental Health Sciences (NIEHS) for the project “A Large-Scale Microfluidics Imaging Platform for High-Throughput Toxicity Testing using Canine Intestinal Organoids”. Currently, toxicology studies require a large number of animal testing to identify better and safer drug candidates. In an attempt to reduce Read more about Newormics awarded an SBIR Phase I grant from the NIEHS[…]

Newormics awarded SBIR Phase I grant from the NIMH

Newormics was awarded an SBIR Phase I grant from the National Institute of Mental Health (NIMH) for the project “A multi-well plate format microfluidic immobilization chip for high-content imaging of whole animals”. Advancements in precise genetic manipulation have helped biologists to identify new drug-targets and in vivo disease mechanisms using small animal models, such as Read more about Newormics awarded SBIR Phase I grant from the NIMH[…]

Introducing the Next Generation Drug Discovery Platforms

Newormics is a developer of the first high-throughput, high-content drug screening platforms for use with in vivo small animal models as well as 3D tissue organoids. The company provides microfluidics-based platforms to advance early stage drug discovery and toxicity studies for faster and better drug development with cost-effective solutions. Newormics is co-founded by Prof. Adela Read more about Introducing the Next Generation Drug Discovery Platforms[…]